Annovis to Host Year-End Investor Webcast on December 11, 2024
November 25, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased...
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
November 12, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
November 11, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
November 07, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies...
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
October 22, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies...
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
October 15, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
October 03, 2024 08:30 ET
|
Annovis Bio, Inc.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer’s Treatment: Innovative...
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
October 02, 2024 08:30 ET
|
Annovis Bio, Inc.
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands...
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
September 30, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for...